New Approaches to Treating Multiple Sclerosis (MS) Using Stem Cells Explore Several Mechanisms Focused on Immunomodulation, Neuroprotection, and Myelin Repair. Here’s a Key Overview:
Main Types of Cell Therapy, Observed Treatment Results, and Mechanisms of Action
- Mesenchymal Stem Cells (MSC)
- Immunomodulation: MSC suppress aggressive T and B lymphocytes, increase regulatory Treg/B cells, reduce inflammatory cytokines (IFNγ, IL-17), and dendritic cell activity.
- Neuroprotection: MSC secrete trophic factors, prevent neuronal apoptosis, and reduce glial scarring.
- Remyelination: Stimulate endogenous neurogenesis and oligodendrogenesis, promote nerve sheath repair.
- Paracrine Effects (Secretome): MSC release exosomes, cytokines, growth factors — their primary therapeutic mechanism.
PAY ATTENTION TO NEW TREATMENT PROTOCOL OF MS: Stem Cell Therapy for Multiple Sclerosis (MS) 2026
- Induced Pluripotent Stem Cells (iPSC) and Neural Precursors
- Reprogram somatic cells into iPSC, then differentiate into oligodendrocytes/neurons and transplant into the CNS. Clinical studies show stimulation of remyelination and motor improvement.
- Placental/Umbilical Cord MSCs
- Already demonstrated safety and functional improvement in patients: reduced MRI activity, improved function (40% without active MS) with intrathecal/intravenous administration.
What is the Primary Mechanism?
- Immunomodulation is the key effect in MSC and aHSCT:
- aHSCT eliminates pathological T clones and helps form a new tolerant immune profile.
- MSC modulate immunity via cytokines, Treg/B cells, suppression of Th1/Th17, and dendritic function.
- Neuroprotection and Remyelination are essential, especially with MSC and iPSC: surviving cell walls, secreted factors, and stimulation of endogenous regeneration.
Crossing the Blood-Brain Barrier (BBB) is Critical in MS Therapy Because:
Why Overcome the BBB in MS Treatment?
- Target Area of Disease — CNS
MS is an autoimmune disease affecting the myelin sheath in the brain and spinal cord. Therefore, therapies, cells, or their derivatives must enter the brain to act not only systemically but also locally:
- suppress inflammation,
- activate remyelination,
- prevent neuronal death.
- The BBB is a Filter
It protects the brain from toxins and pathogens but also blocks most therapeutic substances, including large molecules, cells, and proteins.
Which Stem Cells and Their Derivatives Can Cross the BBB?
| Agent Type | BBB Penetration Method | Features and Mechanisms |
|---|---|---|
| Mesenchymal Stem Cells (MSC) | Usually no (IV delivery → retained in lungs/liver) | Indirect action via secretome; limited penetration during inflammation |
| MSC-derived Exosomes (30–150 nm vesicles) | ✅ Yes, cross BBB via transcytosis | Most promising: carry RNA, proteins, miRNA, immunomodulators, trophic factors |
| Hematopoietic Stem Cells (CD34+) | ❌ Do not cross BBB | Act systemically, “reset” immune system |
| iPSC → Neural Precursors | Yes, with intracranial delivery | Require invasive delivery directly into brain/CSF |
| Neural Stem Cells (NSC) | ✅ Yes, via intrathecal delivery | Can migrate to demyelinated zones and stimulate repair |
| Organelles + miRNA delivery system | ✅ Yes | Can carry growth factors, antioxidants, mRNA |
Why Are Organelles and Vesicles Especially Promising?
- Size: <150 nm → can cross the BBB with systemic delivery (IV, IM, even intranasal).
- Composition: contain anti-inflammatory molecules (miR-146a, TGF-β, HGF), remyelinating proteins and RNA.
- Acellular: do not trigger rejection or tumor growth.
- Clinical Cases: show significant motor improvement and remyelination after administration.
Conclusion:
- BBB penetration is key to effective targeting of MS lesions in the CNS.
- Organelles and vesicles are the most promising agents — small, immune-neutral, biologically active, and BBB-permeable.
- The future of MS therapy lies in engineered organelles combined with nanoparticles carrying remyelinating and immunoregulatory signals.
Expected Results of MS Treatment with Stem Cells or Their Derivatives (Exosomes, Vesicles) Depend On:
- MS type (relapsing-remitting, secondary-progressive, primary-progressive),
- Disability level (EDSS),
- Therapy type (aHSCT, MSC, exosomes),
- Delivery method,
- Disease phase (active inflammation vs chronic damage).
Summary of Clinical Outcomes (by Therapy Type)
| Therapy Type | Patients | Expected Results | Confirmed in Studies |
|---|---|---|---|
| aHSCT (Autologous Hematopoietic) | Relapsing MS, age <50, active MRI | ▸ 60–80% — EDSS stabilization or improvement▸ 50–60% — relapse-free for >5 years▸ MRI lesion reduction | MIST, HALT-MS, BEAT-MS |
| MSC (Mesenchymal Stem Cells) | Progressive + relapsing MS | ▸ 30–40% improved walking (T25FW)▸ Reduced fatigue, spasticity▸ EDSS stability >12 months▸ QoL improvement (SF-36, MSQoL) | MESEMS, MSC-HHS, NCT trials |
| MSC-exosomes / vesicles | Progressive + relapsing MS | ▸ Remyelination, reduced inflammation▸ Immunomodulation without adverse effects | MESEMS, MSC-HHS, NCT trials |
| NSC (Neural Stem Cells) | Chronic forms, spinal MS | ▸ 60% improved motor function▸ Improved sensitivity, urination▸ MRI: slowed atrophy | MESEMS, NCT trials |
| iPSC/Neuro-precursors | Progressive + relapsing MS | ▸ Remyelination and regeneration, invasive delivery required | MESEMS, NCT trials |
Possible Improvements After Cell Therapy
| Area | Potential Improvement | Frequency |
|---|---|---|
| Motor Skills / Coordination | Improved gait, reduced spasticity | 30–50% |
| Fatigue | Reduced neuroinflammation → more energy | 40–60% |
| Sensitivity / Pain | Reduced neuropathy, pain | 20–40% |
| Relapses | Sharp decline in relapses (with aHSCT) | 70–90% |
| Cognitive Function | Improved attention, memory | 10–30% (moderate) |
| MRI Findings | Reduced lesion activity, fewer new lesions | Confirmed |
| Quality of Life | Better well-being, sleep, emotional state | 50+% |
What Should NOT Be Expected
- Complete cure of MS — cell therapy slows or stabilizes MS, but does not “erase” it.
- Immediate effect — improvements typically appear after 3–6 months (or later).
- Universal response — effectiveness varies, especially in advanced disability (EDSS > 6.5).
- Strong effects in progressive forms — often weaker than in active relapsing forms.
Clinical Trial Examples
- MIST Trial (HSCT, 2022):
▸ 69% of patients — no disability progression after 5 years,
▸ 50+% — EDSS improvement by ≥1 point. - MESEMS Trial (MSC):
▸ Safety confirmed,
▸ Motor and cognitive improvements observed. - Phase I/II MSC Study (2023):
▸ 58% improved walking (T25FW),
▸ Improved vision and cognitive testing in some patients.
The data was gathered from patients’ responses to PARQ questionnaires administered at 3, 6, 9, and 12 months following MSC treatment. The questionnaires measured percentage improvement from baseline in various parameters related to memory, physical abilities, sensory function, cognition, libido, sleep quality, and motivation.
STUDY MORE ABOUT MS TREATMENT WITH IPSC : Stem Cell Therapy for Multiple Sclerosis: the Future of iPSC Technology
Our initial 12-month results demonstrate promising improvements in many of these areas, with the most robust gains seen at 9 months post-treatment before tapering off slightly at 12 months. In particular, physical fitness, energy, balance, coordination, reaction time, and stamina showed over 50% enhancement at 9 months. Measures like memory and flexibility were more inconsistent.
INTERESTING TO READ:Stem Cell Therapy for Multiple Sclerosis: Patient Case Study
Conclusion:
If treatment is well selected and professionally conducted:
- 30–70% of patients can expect slowing or halting of disease progression.
- 20–40% will see real symptom improvement.
- Highest efficacy is seen in active relapsing forms with early intervention.
FREE CONTACT WITH DOCTOR
